Missing Script

Get updates

MS-N314 · Exercise and rehabilitation · Cognitive symptoms · Fatigue · Human evidence · Appraised 12 November 2026

Can a short, individually tailored home walking and resistance-band program reduce cognitive symptoms and mental fatigue during chemotherapy?

Evidence at a glance

  • Evidence label: Large multicenter randomized trial secondary-outcome analysis; benefit concentrated in people receiving two-week chemotherapy cycles
  • Benefit: Mental fatigue was modestly lower overall; self-reported cognitive decline was less only in the subgroup receiving chemotherapy every two weeks.
  • Certainty: Moderate for short-term self-reported mental fatigue; low to moderate for cognition because it was a secondary outcome, subgroup-dependent and not objectively tested.
  • Risk: Ten adverse events occurred, including five serious events from cytopenias or multiple-organ failure; the report did not attribute them to the exercise program.

What was studied

Design and population: A nationwide U.S. phase III trial enrolled 693 chemotherapy-naïve adults with nonmetastatic solid tumors at 20 community oncology practices; 687 were randomized (354 EXCAP, 333 usual care). Cognitive data were complete at baseline and six weeks for 547 people. The population was 94% women, 83% breast cancer and 85% non-Hispanic White.

Regimen: EXCAP was a six-week home program introduced in one 60-minute session: daily individualized low-to-moderate intensity walking at 60%–85% heart-rate reserve or perceived exertion 3–5/10, plus daily resistance-band exercise at perceived exertion 3–5/10. Staff called every two weeks. Cognition and mental fatigue were secondary outcomes.

What the evidence found

Among people receiving two-week chemotherapy cycles, EXCAP was associated with less overall self-reported cognitive impairment than usual care (adjusted mean difference 7.0, SE 3.3; P=.04), less perceived impairment (4.1, SE 2.1; P=.05), fewer comments from others (0.6, SE 0.2; P=.02), and less mental fatigue (−1.6, SE 0.5; P<.01). No cognitive advantage was detected with three- or four-week cycles.

Across cycle lengths, mental fatigue favored EXCAP by −0.7 points (SE 0.3; P=.02). Both groups still experienced some worsening during chemotherapy. The report did not establish whether these numerical differences met a patient-defined clinically meaningful threshold.

EXCAP participants maintained walking better and reported resistance-band exercise about three times weekly for 25 minutes, despite the daily prescription. Of 687 randomized, 547 had complete paired cognitive data; dropout was 23% with EXCAP and 17% with usual care.

Ten adverse events were reported: five were serious—four lymphopenia or neutropenia events and one multiple-organ-failure death. The article did not state that these events were caused by exercise.

How to interpret it

This is a substantial pragmatic trial, but the cognitive advantage came from a chemotherapy-schedule subgroup and self-report measures. The paper itself calls for a trial with cognition as the primary outcome and objective testing.

The cytokine analysis is mechanistic and associative; it does not prove that inflammation changes caused the symptom results. The study did not evaluate cancer control.

Practical safety context

A home program still requires screening for cardiopulmonary disease, orthopedic limitations, neuropathy, fall risk, bone metastases and current blood counts. Fever, chest pain, syncope, new neurologic symptoms or severe treatment toxicity require clinical review.

Heart-rate targets may be unreliable with beta-blockers, autonomic dysfunction or some cancer therapies; perceived exertion and individualized professional guidance may be safer.

Questions for the care team

  • Am I medically cleared for walking and resistance work during this cycle?
  • Would an exercise physiologist modify the program for neuropathy, bone disease or cytopenias?
  • Should we track subjective symptoms, objective cognition, or both?

Funding and conflicts

Supported by multiple U.S. National Cancer Institute/NIH grants. The accessible report listed no commercial sponsor for the intervention.

Sources

Last literature search: 12 November 2026. Record appraisal: 12 November 2026. The full report and registry were appraised. This page is educational and does not replace individualized medical advice. These supportive-care outcomes do not establish tumor shrinkage, delayed recurrence or longer survival.